CL2008000717A1 - Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras en un tumor del paciente. - Google Patents

Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras en un tumor del paciente.

Info

Publication number: CL2008000717A1
Authority: CL; Chile
Prior art keywords: patient; forecasting; responding; absence; treatment
Prior art date: 2007-03-13

Application number

CL200800717A

Other languages

English (en)

Inventor

Daniel Juan Todd Radin Freeman

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-13

Filing date

2008-03-11

Publication date

2008-09-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39689242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000717(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-03-11 Application filed by Amgen Inc filed Critical Amgen Inc

2008-09-22 Publication of CL2008000717A1 publication Critical patent/CL2008000717A1/es

Links

101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title 1
230000035772 mutation Effects 0.000 title 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

CL200800717A 2007-03-13 2008-03-11 Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras en un tumor del paciente. CL2008000717A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US90694307P	2007-03-13	2007-03-13

Publications (1)

Publication Number	Publication Date
CL2008000717A1 true CL2008000717A1 (es)	2008-09-22

Family

ID=39689242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200800717A CL2008000717A1 (es)	2007-03-13	2008-03-11	Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras en un tumor del paciente.

Country Status (21)

Country	Link
US (3)	US20080293055A1 (es)
EP (2)	EP2121989B2 (es)
JP (1)	JP2010521153A (es)
AR (1)	AR065687A1 (es)
AU (1)	AU2008226803A1 (es)
CA (1)	CA2680326A1 (es)
CL (1)	CL2008000717A1 (es)
CY (2)	CY1115333T1 (es)
DK (2)	DK2465950T3 (es)
ES (2)	ES2635051T3 (es)
HR (2)	HRP20140360T4 (es)
HU (1)	HUE033695T2 (es)
LT (1)	LT2465950T (es)
MX (1)	MX2009009787A (es)
PE (1)	PE20081880A1 (es)
PL (2)	PL2465950T3 (es)
PT (2)	PT2121989E (es)
RS (2)	RS53265B2 (es)
SI (2)	SI2121989T2 (es)
TW (1)	TW200902553A (es)
WO (1)	WO2008112269A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE520979T1 (de) *	2005-08-24	2011-09-15	Bristol Myers Squibb Co	Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
US8768629B2 (en)	2009-02-11	2014-07-01	Caris Mpi, Inc.	Molecular profiling of tumors
CN103424541B (zh)	2006-05-18	2018-01-30	分子压型学会股份有限公司	确定针对病状的个性化医疗介入的系统和方法
ES2426814T3 (es) *	2007-03-13	2013-10-25	Amgen Inc.	Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr
US8583380B2 (en)	2008-09-05	2013-11-12	Aueon, Inc.	Methods for stratifying and annotating cancer drug treatment options
WO2011109440A1 (en)	2010-03-01	2011-09-09	Caris Life Sciences Luxembourg Holdings	Biomarkers for theranostics
GB2463401B (en)	2008-11-12	2014-01-29	Caris Life Sciences Luxembourg Holdings S A R L	Characterizing prostate disorders by analysis of microvesicles
US8502015B1 (en)	2009-07-06	2013-08-06	Transgenex Nanobiotech, Inc.	Method of inducing cancer
CN102115782B (zh) *	2009-12-30	2014-06-18	北京雅康博生物科技有限公司	用于定量检测K-ras突变的试剂盒
WO2011127219A1 (en)	2010-04-06	2011-10-13	Caris Life Sciences Luxembourg Holdings	Circulating biomarkers for disease
US20130029336A1 (en) *	2010-04-12	2013-01-31	Response Genetics, Inc.	KRAS Primers and Probes
RU2565550C2 (ru)	2010-09-24	2015-10-20	Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити	Прямой захват, амплификация и секвенирование днк-мишени с использованием иммобилизированных праймеров
KR102001686B1 (ko)	2011-04-07	2019-07-18	암젠 인크	신규한 egfr 결합 단백질
CN104039328B (zh) *	2011-11-11	2018-10-09	米伦纽姆医药公司	对蛋白酶体抑制剂的反应的生物标记
GB2533006B (en)	2012-09-04	2017-06-07	Guardant Health Inc	Systems and methods to detect copy number variation
US10876152B2 (en)	2012-09-04	2020-12-29	Guardant Health, Inc.	Systems and methods to detect rare mutations and copy number variation
US20160040229A1 (en)	2013-08-16	2016-02-11	Guardant Health, Inc.	Systems and methods to detect rare mutations and copy number variation
US11913065B2 (en)	2012-09-04	2024-02-27	Guardent Health, Inc.	Systems and methods to detect rare mutations and copy number variation
US20140199405A1 (en) *	2013-01-11	2014-07-17	Abraxis Bioscience, Llc	Method for treating cancer based on mutation status of k-ras
EP2977464A4 (en) *	2013-03-19	2016-10-19	Toppan Printing Co Ltd	PROCEDURE FOR PREDICTING SENSITIVITY TO EGFR HEMMER
ES2660989T3 (es)	2013-12-28	2018-03-27	Guardant Health, Inc.	Métodos y sistemas para detectar variantes genéticas
EP3805404A1 (en)	2014-05-13	2021-04-14	Board of Regents, The University of Texas System	Gene mutations and copy number alterations of egfr, kras and met
WO2017106768A1 (en)	2015-12-17	2017-06-22	Guardant Health, Inc.	Methods to determine tumor gene copy number by analysis of cell-free dna
BR112020025764A2 (pt)	2018-06-19	2021-05-11	Biontech Us Inc.	neoantígenos e usos dos mesmos
CN110357965A (zh) *	2019-06-24	2019-10-22	浙江大学	一种突变型kras特异性抗体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
EP1400536A1 (en)	1991-06-14	2004-03-24	Genentech Inc.	Method for making humanized antibodies
US5470705A (en)	1992-04-03	1995-11-28	Applied Biosystems, Inc.	Probe composition containing a binding domain and polymer chain and methods of use
ATE173767T1 (de)	1992-04-03	1998-12-15	Perkin Elmer Corp	Proben zusammensetzung und verfahren
EP1500329B1 (en)	1996-12-03	2012-03-21	Amgen Fremont Inc.	Human antibodies that specifically bind human TNF alpha
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US6395486B1 (en)	1999-03-15	2002-05-28	Applera Corporation	Probe/mobility modifier complexes for multiplexnucleic acid detection
EP1313880A2 (en)	2000-05-30	2003-05-28	PE Corporation (NY)	Methods for detecting target nucleic acids using coupled ligation and amplification
US6503914B1 (en) *	2000-10-23	2003-01-07	Board Of Regents, The University Of Texas System	Thienopyrimidine-based inhibitors of the Src family
WO2003099205A2 (en)	2002-05-20	2003-12-04	Abgenix, Inc.	Treatment of renal carcinoma using antibodies against the egfr
EP1636380A2 (en)	2003-05-30	2006-03-22	Genomic Health, Inc.	Gene expression markers for response to egfr inhibitor drugs
CN101501211A (zh)	2004-03-31	2009-08-05	综合医院公司	测定癌症对表皮生长因子受体靶向性治疗反应性的方法
EP1766068A4 (en) *	2004-06-04	2010-03-03	Genentech Inc	EGFR Mutations
WO2006047483A2 (en) *	2004-10-22	2006-05-04	Redpath Integrated Pathology, Inc.	Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and pure fluid specimens
US7635570B2 (en)	2005-04-01	2009-12-22	Salvatore Siena	Epidermal growth factor receptor gene copy number
KR20080003422A (ko) *	2005-04-14	2008-01-07	메르크 파텐트 게엠베하	종양 조직 내의 ｅｇｆｒ 유전자의 증가된 복제수에 기초한항-ｅｇｆｒ 항체 치료
PL1913157T5 (pl) *	2005-06-28	2017-09-29	Genentech Inc	Mutacje EGFR i KRAS do prognozowania reakcji pacjenta na leczenie inhibitorem EGFR
US8703769B2 (en) *	2005-07-15	2014-04-22	The University Of North Carolina At Chapel Hill	Use of EGFR inhibitors to prevent or treat obesity
ATE520979T1 (de) *	2005-08-24	2011-09-15	Bristol Myers Squibb Co	Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
US7908091B2 (en) *	2006-03-17	2011-03-15	Prometheus Laboratories Inc.	Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2008033442A2 (en) *	2006-09-12	2008-03-20	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for performing low background multiplex nucleic acid amplification reactions
ES2426814T3 (es) *	2007-03-13	2013-10-25	Amgen Inc.	Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr

2008
- 2008-03-11 AR ARP080100995A patent/AR065687A1/es unknown
- 2008-03-11 EP EP08742061.8A patent/EP2121989B2/en active Active
- 2008-03-11 CA CA002680326A patent/CA2680326A1/en not_active Abandoned
- 2008-03-11 MX MX2009009787A patent/MX2009009787A/es active IP Right Grant
- 2008-03-11 TW TW097108519A patent/TW200902553A/zh unknown
- 2008-03-11 RS RS20140187A patent/RS53265B2/sr unknown
- 2008-03-11 US US12/046,319 patent/US20080293055A1/en not_active Abandoned
- 2008-03-11 EP EP12154109.8A patent/EP2465950B1/en active Active
- 2008-03-11 PE PE2008000451A patent/PE20081880A1/es not_active Application Discontinuation
- 2008-03-11 RS RS20170996A patent/RS56422B1/sr unknown
- 2008-03-11 SI SI200831191T patent/SI2121989T2/sl unknown
- 2008-03-11 HR HRP20140360TT patent/HRP20140360T4/hr unknown
- 2008-03-11 DK DK12154109.8T patent/DK2465950T3/en active
- 2008-03-11 CL CL200800717A patent/CL2008000717A1/es unknown
- 2008-03-11 AU AU2008226803A patent/AU2008226803A1/en not_active Abandoned
- 2008-03-11 JP JP2009553623A patent/JP2010521153A/ja active Pending
- 2008-03-11 ES ES12154109.8T patent/ES2635051T3/es active Active
- 2008-03-11 LT LTEP12154109.8T patent/LT2465950T/lt unknown
- 2008-03-11 WO PCT/US2008/003312 patent/WO2008112269A2/en not_active Ceased
- 2008-03-11 PT PT87420618T patent/PT2121989E/pt unknown
- 2008-03-11 ES ES08742061T patent/ES2458626T5/es active Active
- 2008-03-11 PL PL12154109T patent/PL2465950T3/pl unknown
- 2008-03-11 DK DK08742061.8T patent/DK2121989T4/da active
- 2008-03-11 HU HUE12154109A patent/HUE033695T2/en unknown
- 2008-03-11 SI SI200831873T patent/SI2465950T1/sl unknown
- 2008-03-11 PL PL08742061.8T patent/PL2121989T5/pl unknown
- 2008-03-11 PT PT121541098T patent/PT2465950T/pt unknown
2012
- 2012-06-14 US US13/523,174 patent/US10030270B2/en active Active
2014
- 2014-04-16 CY CY20141100291T patent/CY1115333T1/el unknown
2017
- 2017-07-25 CY CY20171100792T patent/CY1119112T1/el unknown
- 2017-10-09 HR HRP20171509TT patent/HRP20171509T1/hr unknown
2018
- 2018-06-21 US US16/014,056 patent/US11155876B2/en active Active

Also Published As

Publication number	Publication date
DK2121989T3 (da)	2014-04-28
HUE033695T2 (en)	2017-12-28
US20190048423A1 (en)	2019-02-14
PT2465950T (pt)	2017-10-17
AU2008226803A1 (en)	2008-09-18
LT2465950T (lt)	2017-10-10
EP2465950A3 (en)	2013-03-13
RS53265B2 (sr)	2022-06-30
CY1115333T1 (el)	2017-01-04
SI2121989T1 (sl)	2014-06-30
JP2010521153A (ja)	2010-06-24
EP2465950A2 (en)	2012-06-20
DK2465950T3 (en)	2017-10-09
EP2121989A2 (en)	2009-11-25
HRP20140360T4 (hr)	2022-06-10
ES2458626T5 (es)	2022-04-29
PE20081880A1 (es)	2008-12-31
PL2465950T3 (pl)	2017-12-29
US20120264129A1 (en)	2012-10-18
DK2121989T4 (da)	2022-06-20
WO2008112269A2 (en)	2008-09-18
EP2121989B2 (en)	2022-03-09
CY1119112T1 (el)	2018-02-14
RS56422B1 (sr)	2018-01-31
RS53265B (sr)	2014-08-29
US20080293055A1 (en)	2008-11-27
HRP20140360T1 (hr)	2014-05-23
ES2635051T3 (es)	2017-10-02
SI2465950T1 (sl)	2017-11-30
TW200902553A (en)	2009-01-16
US10030270B2 (en)	2018-07-24
PL2121989T3 (pl)	2014-07-31
ES2458626T3 (es)	2014-05-06
EP2121989B1 (en)	2014-01-22
HRP20171509T1 (hr)	2017-11-17
CA2680326A1 (en)	2008-09-18
SI2121989T2 (sl)	2022-05-31
US11155876B2 (en)	2021-10-26
PT2121989E (pt)	2014-04-30
EP2465950B1 (en)	2017-07-12
AR065687A1 (es)	2009-06-24
MX2009009787A (es)	2009-09-22
WO2008112269A3 (en)	2008-11-20
PL2121989T5 (pl)	2023-03-06

Publication	Publication Date	Title
CL2008000717A1 (es)	2008-09-22	Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras en un tumor del paciente.
CL2008000716A1 (es)	2008-09-22	Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras y b-raf en un tumor del paciente.
BRPI0817811A2 (pt)	2014-10-14	Xilanases, ácidos nucleicos que codificam as mesmas e métodos para fabricação e uso das mesmas.
SG10201901076WA (en)	2019-03-28	Methods of treating alzheimer's disease
AR080643A1 (es)	2012-04-25	Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa
ES2570359T3 (es)	2016-05-18	Regiones ultraconservadas que codifican ARNnc
CO6680609A2 (es)	2013-05-31	Composición acuosa que contiene bromhexina
MX2018011832A (es)	2020-09-14	Metodos y composiciones para uso en diagnostico de pacientes con cancer.
ES2530809T3 (es)	2015-03-06	Fragmento de silicio policristalino y procedimiento para la limpieza de fragmentos de silicio policristalino
TW200942466A (en)	2009-10-16	Devices and methods for performing inspections, repairs, and/or other operations within vessels
AU323779S (en)	2009-01-12	Footwear upper
AU326332S (en)	2009-06-11	Footwear upper
BRPI0812856A2 (pt)	2014-12-09	Composições de vacina de emulsão que compreendem antígeno e adjuvante na fase aquosa.
WO2012170776A3 (en)	2013-04-11	Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
MX349011B (es)	2017-07-05	Biomarcadores para terapia de inhibidor de hedgehog.
BRPI1014239A2 (pt)	2016-04-12	"corpo de colmeia que pode ser aquecido em vários estágios"
BR112013017239A2 (pt)	2018-06-05	processo e composição na forma de uma emulsão direta para a tintura ou o clareamento das fibras queratínicas humanas, dispositivo e composição para a tintura ou o clareamento das fibras queratínicas humanas.
NZ703411A (en)	2017-09-29	Use of markers in the diagnosis and treatment of prostate cancer
AU323836S (en)	2009-01-12	Footwear upper
MX2017012320A (es)	2018-01-18	Estandares de antigeno prostatico y sus usos.
BRPI0921012A2 (pt)	2018-10-16	inserto e cortador que pode ser montado com o inserto.
WO2014209905A3 (en)	2015-02-26	Methods and compositions for detecting and diagnosing diseases and conditions
ES2530732T3 (es)	2015-03-05	Procedimientos de diagnóstico para el cáncer de pulmón
AU323778S (en)	2009-01-12	Footwear upper
BRPI1016020A2 (pt)	2017-07-18	linha cirúrgica que compreende células e método de produção da linha.